Skip to main content

Table 5 Percentage utilisation of oral generic risperidone versus total risperidone (DDD basis) and percentage reduction in expenditure per defined daily dose for oral generic risperidone versus pre-patent loss prices by the end of the study period in each country

From: Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications

Country

Utilisation of generic risperidone, %

Price reduction, %

Belgium

52

59

Ireland

14

28

Scotland

98

84

Sweden

96

80